PET/CT在淋巴瘤异质性评估中的价值  

Value of PET/CT in the evaluation of lymphoma heterogeneity

作　　者：詹华英 李伟龙[2] 于丽硕 刘志翔[3] ZHAN Huaying;LI Weilong;YU Lishuo;LIU Zhixiang(School of Medical imaging,Weifang Medical University,Weifang 261000,China;Department of Nuclear Medicine,Yantai Yuhuangding Hospital,Yantai 264000,China;Department of Nuclear Medicine,the Affiliated Hospital of Weifang Medical University,Weifang 261000,China)

机构地区：[1]潍坊医学院医学影像学院,山东潍坊261000 [2]烟台毓璜顶医院核医学科,山东烟台264000 [3]潍坊医学院附属医院核医学科,山东潍坊261000

出　　处：《分子影像学杂志》2024年第2期220-224,共5页Journal of Molecular Imaging

基　　金：山东省医药卫生科技发展计划项目(2017WS876)。

摘　　要：淋巴瘤是一种以淋巴细胞为主要来源的高度异质性肿瘤。^(18)F-FDG PET/CT通过对肿瘤细胞状态和肿瘤微环境变化的异质性FDG摄取进行评估,被广泛用于嗜FDG淋巴瘤分期、再分期及治疗反应评估。但常规PET参数在全面评估肿瘤异质性方面存在不足。本文总结PET/CT在淋巴瘤诊断、分期、治疗及预后评估中的作用,并探讨PET/CT未来发展方向,包括新PET参数的探索、新试剂的开发和人工智能的融合,这些领域在淋巴瘤检测、异质性量化、鉴别、中期疗效评估和预测预后等方面取得了重大突破。Lymphoma,a highly heterogeneous tumor primarily derived from lymphocytes,can be effectively staged,restaged,and assessed for treatment response using ^(18)F-FDG PET/CT.This imaging technique evaluates the heterogeneous FDG uptake in tumor cells and changes in the tumor microenvironment.However,conventional PET parameters alone are insufficient for a comprehensive assessment of tumor heterogeneity.This article provides an overview of the role of PET/CT in diagnosing,staging,treating,and assessing the prognosis of lymphoma.Furthermore,it explores the future development direction of PET/CT,including the investigation of new PET parameters,the development of novel agents,and the integration of artificial intelligence.Significant advancements have been made in tumor detection,quantification of heterogeneity,identification,midterm efficacy evaluation,and prognosis prediction.

关 键 词：淋巴瘤 ^(18)F-FDG PET/CT 肿瘤异质性 

分 类 号：R733.1[医药卫生—肿瘤] R730.44[医药卫生—临床医学]